Posts from December, 2016 - VAR2 Pharmaceuticals

The role of oncofetal CSA is published in a major article Thursday, 01 December 2016

Best poster presentation at EMBO Cancer meeting!

Uncategorized 19 September 2018

It is with great pleasure we can announce that Dr. Nader Al-Nakouzi was awarded The FEBS Journal Best Poster Prize for the poster "Expression and regulation of oncofetal chondroitin sulfate in prostat...

Presentation of VAR2-based immunotherapy at the 9th CDD Conference on Cancer

Uncategorized 16 September 2018

Co-founder and executive Chairman of the Board of directors, Dr. Mads Daugaard, are to present data on VAR2-based immunotherapy in the context of the cancer microenvironemnt at the 9th CDD Confer...

Presenting at EMBO Workshop Cellular signalling and cancer therapy, 14 – 18 September 2018

Uncategorized 13 September 2018

Our Research Scientist Dr. Nader Al-Nakouzi, will present new exciting data on oncofetal Chondrotin sulfat A in prostate cancer at the Cellular signalling and cancer therapy EMBO workshop, taking plac...

Nordic Life Science Days 2018

Uncategorized 10 September 2018

VAR2 Pharmaceuticals/VarCT Diagnostics will be at the Nordic Life Science Days in Stockholm 10-12 September 2018. We look forward to meet old and new partners in the Life Science business.

Our Investors

VAR2 Pharmaceuticals is owned by the inventor group and University of Copenhagen, and we are financed by private investors.

Want to be a partner?

To discuss a potential partnership opportunity with VAR2 Pharmaceuticals please contact us